Zenas BioPharma (ZBIO) Current Assets (2023 - 2026)

Zenas BioPharma's Current Assets history runs 4 years deep, the most recent figure standing at $730.2 million for Q1 2026.

• On a quarterly basis, Current Assets rose 129.75% year-over-year to $730.2 million in Q1 2026; TTM through Mar 2026 was $730.2 million, a 129.75% increase from a year earlier, with the FY2025 full-year figure at $351.2 million, down 1.34% from the prior year.
• Current Assets advanced to $730.2 million in Q1 2026 per ZBIO's latest filing, from $351.2 million in the prior quarter.
• Across five years, Current Assets topped out at $730.2 million in Q1 2026 and bottomed at $59.8 million in Q4 2023.
• The 4-year median for Current Assets is $334.5 million (2025), against an average of $348.0 million.
• Across the five-year window, Current Assets soared 495.15% in 2024 and declined 24.67% in 2025, its largest moves.
• Year by year, Current Assets stood at $59.8 million in 2023, then surged by 495.15% to $355.9 million in 2024, then decreased by 1.34% to $351.2 million in 2025, then jumped by 107.92% to $730.2 million in 2026.
• Per Business Quant, the three latest ZBIO Current Assets figures stand at $730.2 million (Q1 2026), $351.2 million (Q4 2025), and $296.6 million (Q3 2025).